Normalized Pre-Tax Income: A company's income before income tax expense smoothed out by removing non-recurring items.
Akari Therapeutics PLC (AKTX) had Normalized Pre-Tax Income of $-15.31M for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
-- |
|
$-14.46M |
|
-- |
|
-- |
|
$15.76M |
|
$-15.76M |
|
$0.44M |
|
$-15.31M |
|
|
Normalized Pre-Tax Income |
$-15.31M |
$-14.46M |
|
$-14.46M |
|
$-14.46M |
|
$-14.46M |
|
$-15.76M |
|
$-15.76M |
|
1.48B |
|
1.48B |
|
$0.00 |
|
$0.00 |
|
| Balance Sheet Financials | |
$3.59M |
|
-- |
|
$30.30M |
|
$33.89M |
|
$13.41M |
|
-- |
|
$6.09M |
|
$19.51M |
|
$14.38M |
|
$-15.92M |
|
$14.38M |
|
1.14B |
|
| Cash Flow Statement Financials | |
$-2.49M |
|
-- |
|
$0.05M |
|
$5.26M |
|
$2.83M |
|
$-2.44M |
|
$0.30M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.27 |
|
-- |
|
-- |
|
-- |
|
0.05 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-2.49M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-100.52% |
|
90.80% |
|
-42.65% |
|
-100.52% |
|
$0.01 |
|
$-0.00 |
|
$-0.00 |
|